Mishriky John, Stupans Ieva, Chan Vincent
School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Discipline of Pharmacy, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, 3083, Australia.
Int J Clin Pharm. 2019 Apr;41(2):538-545. doi: 10.1007/s11096-019-00804-8. Epub 2019 Mar 16.
Background Codeine is the most commonly used opioid worldwide, and is available over-the-counter (OTC) in many countries. There is continual debate regarding the risk:benefit profile for OTC codeine. In Australia, codeine containing analgesics became 'prescription only medicine' from February 2018. However, there is currently limited knowledge on the views of community pharmacists on this upscheduling and the perceived impacts on clinical practice. Objective To investigate the views of community pharmacists on the recent codeine upscheduling in Australia. Setting Community pharmacists in Australia, predominately recruited from Victoria. Method A descriptive cross-sectional study was conducted using a pre-tested customised anonymous self-administered online questionnaire between March and May 2018. To capture a broad range of demographics, pharmacists were recruited via local industry contacts and the Pharmaceutical Society newsletter, with further recruitment through snowball sampling. Main outcome measure Pharmacists' opinions to targeted questions regarding the perceived advantages and disadvantages of the recent 2018 codeine rescheduling from both their perspectives and their perceived impact on patients. Results A total of 113 pharmacists completed the survey. Approximately 43% of pharmacists agreed/strongly agreed that they believed upscheduling will positively impact their ability to manage pain; while 30% were neutral. Approximately 54% of pharmacists agreed/strongly agreed that they believed upscheduling will positively benefit their patients; while 25% were neutral. Perceived advantages for codeine upscheduling included: increased pharmacist/patient engagement, and less codeine use leading to better overall risk:benefit outcome; while disadvantages included: fewer analgesic options, and increased burden for patients, General Practitioners, and the health system. Conclusion This study showed that the current views on the recent codeine upscheduling are quite mixed, with both advantages and disadvantages perceived. Improving education and up-skilling in this space is essential.
可待因是全球使用最广泛的阿片类药物,在许多国家可非处方购买。关于非处方可待因的风险效益比一直存在争议。在澳大利亚,含可待因的镇痛药自2018年2月起成为“仅凭处方购买的药品”。然而,目前对于社区药剂师对此次药品上调级别举措的看法以及对临床实践的感知影响了解有限。
调查澳大利亚社区药剂师对近期可待因上调级别的看法。
主要从维多利亚州招募的澳大利亚社区药剂师。
2018年3月至5月期间,使用预先测试的定制匿名在线自填问卷进行描述性横断面研究。为涵盖广泛的人口统计学特征,通过当地行业联系人及药学会通讯招募药剂师,并通过滚雪球抽样进一步招募。
药剂师对关于2018年可待因重新分级的感知利弊的针对性问题的看法,以及他们对患者的感知影响。
共有113名药剂师完成了调查。约43%的药剂师同意/强烈同意他们认为上调级别将对其疼痛管理能力产生积极影响;而30%持中立态度。约54%的药剂师同意/强烈同意他们认为上调级别将对患者产生积极益处;而25%持中立态度。可待因上调级别的感知优势包括:药剂师/患者互动增加,可待因使用减少导致总体风险效益结果更好;而劣势包括:镇痛选择减少,患者、全科医生和卫生系统负担增加。
本研究表明,目前对近期可待因上调级别的看法喜忧参半,既有优势也有劣势。在这方面加强教育和提升技能至关重要。